Quantification Of Dihydroartemisinin, Artesunate and Artemisinin in Human Blood: Overcoming the Technical Challenge of Protecting the Peroxide Bridge — Niklas Lindegårdh (2011) | RDL Network
Quantification Of Dihydroartemisinin, Artesunate and Artemisinin in Human Blood: Overcoming the Technical Challenge of Protecting the Peroxide Bridge
Bioanalysis 3(14): 1613-1624
Article 2011 English
Authors
NL
Niklas Lindegårdh
WH
Warunee Hanpithakpong
BK
Benjamas Kamanikom
Abstract
1 min read
Quantification of artemisinin (ARN) and its derivatives in whole blood has hitherto been thought impossible.A LC-MS/MS method for the analysis of artesunate (ARS), its metabolite dihydroartemisinin (DHA) and artemisinin in human whole blood has been developed and successfully validated. The method includes stabilization of the blood matrix at the time of collection and at the time of analysis. Addition of potassium dichromate to the blood samples deactivated the Fe(2+) core in hemoglobin, while deferoxamine chelated Fe(3+) and prevented back conversion into Fe(2+). A pilot study showed that the blood:plasma ratio for ARS and DHA is approximately 0.75, indicating a significantly lower uptake in red blood cells than had previously been estimated using radiolabeled drug methodology.The developed LC-MS/MS assay is the first method available for quantification of ARN and its derivatives in blood and opens up new possibilities of studying these drugs inside infected red blood cells.
Rose McGready, Aung Pyae Phyo, Marcus J. Rijken, Joel Tärning, Niklas Lindegårdh, Warunee Hanpithakpon, Hla Hla Than, Nathar Hlaing, Naw Thida Zin, Pratap Singhasivanon, Sir Nicholas White, François Nosten
Niklas Lindegårdh, Joel Tärning, Pham Van Toi, Tran Tinh Hien, Jeremy Farrar, Pratap Singhasivanon, Sir Nicholas White, Michael Ashton, Nicholas P. J. Day
Niklas Lindegårdh, Warunee Hanpithakpong, Benjamas Kamanikom, Pratap Singhasivanon, Duong Socheat, Poravuth Yi, Arjen M. Dondorp, Rose McGready, François Nosten, Sir Nicholas White, Nicholas Day
Discussion(0)
No comments yet. Be the first to comment.